- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07486986
Endokrina störningar, menopaus och sömnproblem hos kvinnor med typ 2-diabetes: Effekter på hjärt-kärlhälsan (EMPOWER)
Endokrin störning, menopaus och dålig sömn hos kvinnor med typ 2-diabetes: Effekter på hjärt-kärlhälsan
EMPOWER aims to determine the overall effect of menopause and sleep disruption on cardiac remodeling in women with type 2 diabetes.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The EMPOWER prospective cohort study is part of a larger project. This interdisciplinary project will utilize animal models, clinical cohorts, epidemiological datasets and data from randomized control trials to explore the hypothesis that sleep disruption and menopause-induced hormonal changes synergistically increase systemic inflammation and impair incretin signaling, leading to worsened cardiac function, heightened cardiometabolic dysfunction, and accelerated CVD risk.
The EMPOWER study aims to determine the cumulative effect of multiple exposures including menopause progression and sleep disruption on subclinical cardiac remodeling in women with T2DM in the perimenopausal transition and if these relationships are moderated by T2DM management, Body Mass Index (BMI), or inflammation.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Carolyn Van Dam
- Telefonnummer: 613-696-7000
- E-post: CVandam@ottawaheart.ca
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
The study population will be selected from patients at the University of Ottawa Heart Institute, The Ottawa Hospital, and from within the Ottawa and surrounding area community.
Beskrivning
Inclusion Criteria:
- Female Sex
- Age range 48-58 years
- In menopausal transition phase (pre-menopause or peri-menopause)
- Diagnosis of Type 2 Diabetes Mellitus
- Have access to and regularly use a smartphone with internet access
Exclusion Criteria:
- Male Sex
- Currently Pregnant
- Prior history of total hysterectomy or bilateral oophorectomy
- Prior diagnosis of any of the following:
Coronary Vascular Disease (CVD) including coronary heart disease, heart failure, congenital heart disease stroke/transient ischemic attack, valvular heart disease, peripheral vascular disease, aortapathy, atrial fibrillation or flutter, other CVD.
- Untreated serious mental illness (e.g, untreated psychosis).
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Evaluation
This is a non-randomized study following individuals in perimenopause with type 2 diabetes. The population will follow a 4 evaluation/observation period with associated questionnaires and medical exams, including bloodwork and cardiac echo. |
The intervention in this study is the additional clinical evaluations for women with type 2 DM and in perimenopause. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Reduced septal e' velocity
Tidsram: Baseline to 4 years.
|
Indicates impaired relaxation of the left ventricle during early diastole; key marker for diastolic dysfunction. Measured by echocardiography. |
Baseline to 4 years.
|
|
Increased E/e' ratio
Tidsram: Baseline to 4 years.
|
Indicates elevated left ventricular filling pressure; key marker for diastolic dysfunction. Measured by echocardiography. |
Baseline to 4 years.
|
|
Increased tricuspid regurgitation (TR) velocity
Tidsram: Baseline to 4 years.
|
Indicates elevated right ventricular systolic pressure or pulmonary hypertension. Measured by echocardiography. |
Baseline to 4 years.
|
|
Change in pulmonary artery systolic pressure (PASP)
Tidsram: Baseline to 4 years.
|
Measures the pressure in the pulmonary artery when the heart beats. Measured by echocardiography. |
Baseline to 4 years.
|
|
Change in E/A ratio
Tidsram: Baseline to 4 years.
|
Decrease of E/A ratio below 1 indicates diastolic dysfunction, and an increase of E/A ratio over 2 indicates advance failure. Measured by echocardiography. |
Baseline to 4 years.
|
|
Change in left atrial size
Tidsram: Baseline to 4 years.
|
Left Atrial Enlargement (LAE) is abnormal stretching or widening of the upper left heart chamber, typically caused by chronic pressure or volume overload. Measured by echocardiography. |
Baseline to 4 years.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Decline in left ventricular global longitudinal strain (GLS)
Tidsram: Baseline to 4 years.
|
Detects heart muscle dysfunction. Measured by echocardiography. |
Baseline to 4 years.
|
|
Decline in left atrial strain
Tidsram: Baseline to 4 years.
|
Indicates left ventricular diastolic dysfunction, heart failure with preserved ejection fraction, and atrial fibrillation. Measured by echocardiography. |
Baseline to 4 years.
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Kerri Anne Mullen, Ph.D., Ottawa Heart Institute Research Corporation
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 20260060-01H
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .